Akeso (SZSC:9926) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

9926 Panoramica delle azioni

Akeso, Inc. è una società biofarmaceutica che ricerca, sviluppa, produce e commercializza farmaci anticorpi.

9926 analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	6/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Negoziato a 51.4% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 7.16% all'anno

Analisi del rischio

Prezzo delle azioni volatile negli ultimi 3 mesi

Gli azionisti sono stati diluiti nell'ultimo anno

Akeso, Inc. Concorrenti

Innovent Biologics

SEHK:1801

HK$76.0b

Ascentage Pharma Group International

SEHK:6855

HK$12.4b

Shanghai Henlius Biotech

SEHK:2696

HK$12.4b

Sichuan Kelun-Biotech Biopharmaceutical

SEHK:6990

HK$39.4b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Akeso
Prezzi storici delle azioni
Prezzo attuale dell'azione	HK$63.95
Massimo di 52 settimane	HK$72.55
Minimo di 52 settimane	HK$26.45
Beta	0.52
1Variazione di 1 mese	41.33%
Variazione a 3 mesi	69.40%
Variazione di 1 anno	77.64%
3Variazione a 3 anni	49.42%
Variazione a 5 anni	n/a
Variazione dall'IPO	69.40%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	9926	HK Biotechs	HK Mercato
7D	-2.4%	8.5%	10.9%
1Y	77.6%	-7.9%	13.4%

Ritorno vs Industria: 9926 ha superato il Hong Kong Biotechs che ha restituito -26.1 % nell'ultimo anno.

Rendimento vs Mercato: 9926 ha superato il mercato Hong Kong che ha restituito 6.2 % nell'ultimo anno.

Volatilità dei prezzi

Is 9926's price volatile compared to industry and market?
9926 volatility
9926 Average Weekly Movement	9.6%
Biotechs Industry Average Movement	7.4%
Market Average Movement	6.8%
10% most volatile stocks in HK Market	13.8%
10% least volatile stocks in HK Market	3.5%

Prezzo delle azioni stabile: Il prezzo delle azioni di 9926 è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 9% ) di 9926 è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni Hong Kong.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2012	2,815	Michelle Xia	www.akesobio.com

Akeso, Inc. è un'azienda biofarmaceutica che ricerca, sviluppa, produce e commercializza farmaci anticorpo. L'azienda sviluppa AK104, un anticorpo bi-specifico PD-1/CTLA-4 per il trattamento del carcinoma della cervice uterina, del carcinoma gastrico (GC), della giunzione gastroesofagea (GEJ), dell'ESCC, del carcinoma epatocellulare (HCC), del carcinoma polmonare a piccole cellule (SCLC), del carcinoma polmonare non a piccole cellule (NSCLC), del carcinoma pancreatico e dei tumori solidi; e AK112, un anticorpo bi-specifico PD-1/VEGF per il trattamento di NSCLC, carcinoma mammario triplo negativo (TNBC), carcinoma della testa e del collo, HCC, carcinoma del colon-retto e dell'ovaio e tumori solidi. Sta inoltre sviluppando AK117, un anticorpo monoclonale CD47 per il trattamento della sindrome mielodisplastica, della leucemia mieloide acuta, del GC, della GEJ, dell'ESCC, dell'HNSCC, del CRC, del TNBC e dei tumori solidi/linfomi; AK105, un anticorpo monoclonale PD-1 per il trattamento del linfoma di Hodgkin classico (R/R cHL), NSCLC, NPC, HCC, SCLC, carcinoma della tiroide, mesotelioma e carcinoma timico, ESCC, UC, GC, GEJ, colangiocarcinoma, tumore neuroendocrino e tumore solido con deficit di mismatch repair; AK119, un anticorpo monoclonale CD73 per il trattamento di tumori solidi e NSCLC; e AK109, un anticorpo monoclonale VEGFR-2 per il trattamento di GC, GEJ, NSCLC, HCC e tumori solidi.

Akeso, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Akeso con la sua capitalizzazione di mercato?
9926 statistiche fondamentali
Capitalizzazione di mercato	HK$55.37b
Guadagni(TTM)	-HK$815.69m
Ricavi(TTM)	HK$2.08b

28.1x

Rapporto P/S

-71.5x

Rapporto P/E

9926 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
9926 Conto economico (TTM)
Ricavi	CN¥1.87b
Costo del fatturato	CN¥141.91m
Profitto lordo	CN¥1.73b
Altre spese	CN¥2.47b
Guadagni	-CN¥735.33m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.85
Margine lordo	92.43%
Margine di profitto netto	-39.24%
Rapporto debito/patrimonio netto	64.2%

Come si è comportato 9926 nel lungo periodo?

Vedi performance storica e confronto

9926 Panoramica delle azioni

Premi

Analisi del rischio

Akeso, Inc. Concorrenti

SEHK:1801

HK$76.0b

SEHK:6855

HK$12.4b

SEHK:2696

HK$12.4b

SEHK:6990

HK$39.4b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Akeso's Ivonescimab Plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety At ESMO 2024

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)

Akeso, Inc. to Report Q2, 2024 Results on Aug 28, 2024

Akeso, Inc. Announces Ivonescimab (Pd-1/Vegf) Received Priority Review from China's Nmpa for First-Line Treatment of Pd-L1 Positive Nsclc

Akeso, Inc. Announces That the First Patient Enrolled in the US Phase 2 Combination Therapy of it's Ligufalimab with Azacitidine for Myelodysplastic Syndrome

Akeso's Sbla for Ivonescimab in 1L Treatment of Pd-L1 Positive Nsclc Accepted by NMPA

Recent updates

Akeso's Ivonescimab Plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety At ESMO 2024

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)

Akeso, Inc. to Report Q2, 2024 Results on Aug 28, 2024

Akeso, Inc. Announces Ivonescimab (Pd-1/Vegf) Received Priority Review from China's Nmpa for First-Line Treatment of Pd-L1 Positive Nsclc

Akeso, Inc. Announces That the First Patient Enrolled in the US Phase 2 Combination Therapy of it's Ligufalimab with Azacitidine for Myelodysplastic Syndrome

Akeso's Sbla for Ivonescimab in 1L Treatment of Pd-L1 Positive Nsclc Accepted by NMPA

Akeso, Inc. Announces Appointment of Bing C. Wang as Chief Financial Officer

New major risk - Share price stability

Akeso, Inc. Announces Change of Directors

Akeso, Inc. Announces Change of Directors

Akeso, Inc., Annual General Meeting, Jun 30, 2024

Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival

New minor risk - Share price stability

Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection

Investor sentiment deteriorates as stock falls 24%

Full year 2023 earnings released: EPS: CN¥2.42 (vs CN¥1.42 loss in FY 2022)

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer

New minor risk - Shareholder dilution

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Full year 2023 earnings released: EPS: CN¥2.42 (vs CN¥1.42 loss in FY 2022)

Investor sentiment improves as stock rises 15%

Akeso, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC

Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

Akeso, Inc. Announces Innovative Clinical Development Roadmap

Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer

Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023

Akeso Publishes Results from Three Investigator-Initiated Trials

Founder recently sold HK$96m worth of stock

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

Co-Founder recently sold HK$4.4m worth of stock

Investor sentiment improves as stock rises 17%

Akeso Announces Results of Phase Ib Clinical Trial for PD-1/VEGF Bispecific Antibody

Akeso Announces the Publication of the Phase 1a/1b First-In-Human Study

Akeso, Inc. Announces Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)

Akeso, Inc. Announces FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes

First half 2023 earnings released: EPS: CN¥3.02 (vs CN¥0.77 loss in 1H 2022)

New major risk - Revenue and earnings growth

Akeso Inc. Announces Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-Line PD-L1 Positive Advanced NSCLC

Akeso, Inc. Announces the National Medical Products Administration Accepts the New Drug Application for the Ebdarokimab Injection (IL-12/IL-23 Monoclonal Antibody, AK101)

Akeso Inc. Announces First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-Line Treatment of Squamous NSCLC

Akeso, Inc. to Report First Half, 2023 Results on Aug 29, 2023

New minor risk - Share price stability

Akeso, Inc., Annual General Meeting, Jun 28, 2023

NMPA Accepts Akeso's Ebronucimab (PCSK9 ) Marketing Application in Two Cardiovascular Indications

No longer forecast to breakeven

Full year 2022 earnings released: CN¥1.42 loss per share (vs CN¥1.32 loss in FY 2021)

Forecast to breakeven in 2023

Akeso, Inc. Announces China NMPA Approved Anniko (Penpulimab) for First-Line Treatment of Locally Advanced or Metastatic Squamous NSCLC

Akeso Inc. Announces JITC publication of Akeso's Ligufalimab(CD47 monoclonal antibody) Mechanism Shows Promising Antitumor Efficacy and Favorable Safety Profile

Forecast to breakeven in 2023

No longer forecast to breakeven

Less than half of directors are independent

Akeso, Inc. Announces Ivonescimab Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China